Mixed Adenosquamous Cell Carcinoma of the Prostate with Paired Sequencing on the Primary and Liver Metastasis

• Published in: Current oncology (Toronto) Vol. 31; no. 5; pp. 2393 - 2399
• Main Authors: Oyogoa, Emmanuella, Sonpatki, Maya, Brinkerhoff, Brian T, Andeen, Nicole, Meyer, Haley, Ryan, Christopher, Sokolova, Alexandra O
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.05.2024
• Subjects: Cancer; Carcinoma, Adenosquamous - drug therapy; Carcinoma, Adenosquamous - genetics; Carcinoma, Adenosquamous - pathology; Carcinoma, Adenosquamous - secondary; Care and treatment; Cell differentiation; Chemotherapy; Development and progression; Health aspects; Humans; Liver cancer; Liver Neoplasms - secondary; Male; Metastasis; Middle Aged; mixed adenosquamous cell carcinoma of the prostate; Prostate cancer; prostate-specific membrane antigen positron emission tomography (PSMA PET); Prostatic Neoplasms - genetics; Prostatic Neoplasms - pathology; Radiotherapy; Squamous cell carcinoma; squamous cell carcinoma of the prostate; mixed adenosquamous cell carcinoma of the prostate; prostate cancer; prostate-specific membrane antigen positron emission tomography (PSMA PET); squamous cell carcinoma of the prostate
• DOI: 10.3390/curroncol31050178
• ISSN: 1718-7729; 1198-0052

This report aims to shed light on the intricate challenges encountered during the diagnosis and treatment of an uncommon variant of prostate cancer-mixed adenosquamous cell carcinoma of the prostate. Prostate cancers of this nature pose distinctive diagnostic and therapeutic dilemmas due to their rarity and complex histological composition. We present a case of a 63-year-old man with metastatic prostate cancer, featuring adenocarcinoma with squamous cell differentiation, who underwent a multimodal treatment approach. The patient responded to first-line carboplatin, docetaxel, and androgen deprivation therapy, followed by androgen receptor pathway inhibitor (ARPI) maintenance. However, disease progression led to radiation therapy and a subsequent switch to Lutetium (177Lu) vipivotide tetraxetan after chemotherapy challenges. Comprehensive genetic profiling revealed shared mutations in the prostate and liver lesions, emphasizing the role of targeted therapies. Prostate-specific membrane antigen (PSMA)-targeted therapy resulted in a notable PSA decline. This case highlights the evolving treatment landscape for rare prostate cancers, integrating genetic insights for tailored interventions. In conclusion, squamous cell carcinoma (SCC) of the prostate is rare, emphasizing the imperative for enhanced comprehension in diagnosis and management. Our case suggests the potential efficacy of ARPI and PSMA-targeted therapies. Our findings advocate for a more nuanced approach to the management of this rare prostate cancer variant, leveraging genomic insights for personalized treatment strategies. This exploration serves as a foundation for further research and clinical considerations in addressing the challenges posed by mixed adenosquamous cell carcinoma of the prostate.